Prognostic factors associated with local recurrence, metastases, and tumor-related death in patients with synovial sarcoma

被引:34
作者
de Silva, MVC
McMahon, AD
Reid, R [1 ]
机构
[1] Univ Glasgow, Western Infirm, Dept Pathol, Scottish Bone Tumour Registry, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Colombo, Fac Med, Dept Pathol, Colombo, Sri Lanka
[3] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2004年 / 27卷 / 02期
关键词
synovial sarcoma; metastases; recurrence; prognosis; histology;
D O I
10.1097/01.coc.0000047129.97604.D6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prognostic factors associated with local recurrence, metastases, and tumor-related death in synovial sarcoma were studied in 51 patients in the Scottish Bone Tumor Registry from 1955 to 1999. In a multivariate analysis, the presence of poorly differentiated (PD) areas was the strongest prognostic factor associated with local recurrence (Hazard ratio [HR] = 11.3, 95% Cl 2.3, 122.5, p = 0.033), metastases (HR = 16.9, 95% Cl 2.3,122.5, p = 0.005), and tumor-related death (HR = 6.9, 95% Cl 1.1,41.8, p = 0.036). Other significant independent risk factors included bone invasion (HR = 16.6, 95% Cl 1.1, 252.5, p = 0.043) and necrosis (HR = 5.1, 95% Cl 1.4, 18.99,p = 0.016) for metastases and bone invasion (HR = 17.6, 95% Cl 1.2, 253.2, p = 0.035) for tumor-related death. Increasing percentages of PD areas and necrosis were associated with increasing hazard ratios for metastases and death. In the univariate analysis, PD areas, tumor size, and a mitotic count over 10/10 high-power fields were significantly associated with recurrence, whereas necrosis, vascular invasion, and age more than 25 years were additional risk factors for metastases and death. Local recurrence was significantly associated with increased risks for metastases (OR = 6.8, 95% Cl 1.6, 28.7, p = 0.006), and death (all cases). Histologic features such as PD areas, necrosis, vascular invasion, and bone invasion should be considered when deciding about adjuvant therapy.
引用
收藏
页码:113 / 121
页数:9
相关论文
共 50 条
[1]  
Bergh P, 1999, CANCER-AM CANCER SOC, V85, P2596, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2596::AID-CNCR16>3.0.CO
[2]  
2-K
[3]  
BRODSKY JT, 1992, CANCER-AM CANCER SOC, V70, P484, DOI 10.1002/1097-0142(19920715)70:2<484::AID-CNCR2820700217>3.0.CO
[4]  
2-7
[5]  
CADMAN NL, 1965, CANCER, V18, P613, DOI 10.1002/1097-0142(196505)18:5<613::AID-CNCR2820180510>3.0.CO
[6]  
2-V
[7]  
CAGLE LA, 1987, CANCER, V59, P1810, DOI 10.1002/1097-0142(19870515)59:10<1810::AID-CNCR2820591021>3.0.CO
[8]  
2-R
[9]   IDENTIFICATION OF NOVEL GENES, SYT AND SSX, INVOLVED IN THE T(X18)(P11.2Q11.2) TRANSLOCATION FOUND IN HUMAN SYNOVIAL SARCOMA [J].
CLARK, J ;
ROCQUES, PJ ;
CREW, AJ ;
GILL, S ;
SHIPLEY, J ;
CHAN, AML ;
GUSTERSON, BA ;
COOPER, CS .
NATURE GENETICS, 1994, 7 (04) :502-508
[10]   DISTINCT XP11.2 BREAKPOINT REGIONS IN SYNOVIAL SARCOMA REVEALED BY METAPHASE AND INTERPHASE FISH - RELATIONSHIP TO HISTOLOGIC SUBTYPES [J].
DELEEUW, B ;
SUIJKERBUIJK, RF ;
WEGHUIS, DO ;
MELONI, AM ;
STENMAN, G ;
KINDBLOM, LG ;
BALEMANS, M ;
VANDENBERG, E ;
MOLENAAR, WM ;
SANDBERG, AA ;
VANKESSEL, AG .
CANCER GENETICS AND CYTOGENETICS, 1994, 73 (02) :89-94